AR106658A1 - ASCT2 SPECIFIC UNION MOLECULES AND THEIR USES - Google Patents
ASCT2 SPECIFIC UNION MOLECULES AND THEIR USESInfo
- Publication number
- AR106658A1 AR106658A1 ARP160103442A ARP160103442A AR106658A1 AR 106658 A1 AR106658 A1 AR 106658A1 AR P160103442 A ARP160103442 A AR P160103442A AR P160103442 A ARP160103442 A AR P160103442A AR 106658 A1 AR106658 A1 AR 106658A1
- Authority
- AR
- Argentina
- Prior art keywords
- asct2
- binding molecules
- aspects
- cells
- antibodies
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Moléculas de unión a ASCT2, por ejemplo, anticuerpos anti-ASCT2 y fragmentos de unión al antígeno de los mismos. En determinados aspectos, las moléculas de unión a ASCT2 están conjugadas con fármacos citotóxicos, por ejemplo, conjugados de anticuerpo anti-ASCT2-fármaco (ADC). En algunos aspectos, los anticuerpos anti-ASCT2 y fragmentos de los mismos pueden ser anticuerpos monoclonales de murino derivados de hibridomas y versiones humanizadas de los mismos. En otros aspectos, las moléculas de unión a ASCT2 se unen específicamente a células que expresan ASCT2 y, en algunos casos, se internalizan en las células. Además, esta divulgación provee composiciones y métodos de diagnóstico y tratamiento de enfermedades o trastornos caracterizados por una sobreexpresión de ASCT2, por ejemplo, algunos tipos de cáncer. En una forma de realización particular, la divulgación provee métodos para tratar el cáncer usando los ADC ASCT2.ASCT2 binding molecules, for example, anti-ASCT2 antibodies and antigen binding fragments thereof. In certain aspects, the ASCT2 binding molecules are conjugated with cytotoxic drugs, for example, anti-ASCT2-drug antibody (ADC) conjugates. In some aspects, the anti-ASCT2 antibodies and fragments thereof can be murine monoclonal antibodies derived from hybridomas and humanized versions thereof. In other aspects, the ASCT2 binding molecules specifically bind to cells that express ASCT2 and, in some cases, are internalized in the cells. In addition, this disclosure provides compositions and methods of diagnosis and treatment of diseases or disorders characterized by an overexpression of ASCT2, for example, some types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253371P | 2015-11-10 | 2015-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106658A1 true AR106658A1 (en) | 2018-02-07 |
Family
ID=61247556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103442A AR106658A1 (en) | 2015-11-10 | 2016-11-10 | ASCT2 SPECIFIC UNION MOLECULES AND THEIR USES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106658A1 (en) |
-
2016
- 2016-11-10 AR ARP160103442A patent/AR106658A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| CY1123884T1 (en) | ENANTI-CD123 ANTIBODIES AND THEIR CONJUGATES AND DERIVATIVES | |
| BR112017019978A2 (en) | antibody or antigen-binding fragment, conjugate, antigen receptor, strand, strand conjugate, fusion protein, t-cell, polynucleotide, vector, ex vivo cell, method of producing a chain, method of producing an antibody, pharmaceutical composition , method for treating cancer, glycopeptide, method for generating an antibody | |
| EA201891040A1 (en) | ANTIBODY CONJUGATES CONTAINING AGENTISTS OF TALL-SIMILAR RECEPTOR | |
| AR106570A1 (en) | ANTI-PSMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN PSMA AND CD3, AND USES OF THESE | |
| BR112017025080A2 (en) | anti-cd123 antibody drug conjugated compound, antibody drug conjugated composition, method of treating a patient having a cd123 expressing cancer, pharmaceutical composition, and intact antibody or antigen binding fragment | |
| PE20181399A1 (en) | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | |
| CL2020003071A1 (en) | Multispecific binding proteins and enhancements with them | |
| MX2017015811A (en) | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways. | |
| AR102698A1 (en) | ANTIBODIES AGAINST CD73 AND ITS USES | |
| AR102649A1 (en) | ANTI-CADHERINA-P ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| NI201300099A (en) | CYTOSOLIC ANTI-PEPTID ANTIBODIES | |
| AR091605A1 (en) | ANTI-MESOTHELINE UNION PROTEINS | |
| CR20190346A (en) | Anti-ccr7 antibody drug conjugates | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| CO2018004930A2 (en) | Specific binding molecules for asct2 | |
| CY1123275T1 (en) | BINDING MOLECULES SPECIFICALLY FOR IL-21 AND USES THEREOF | |
| MX2020004381A (en) | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof. | |
| UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
| MX2019015042A (en) | Dosage regimes for the administration of an anti-cd19 adc. | |
| CO7240362A2 (en) | IL-6 binding molecule | |
| NI202000051A (en) | MONOCLONAL ANTIBODIES AND METHODS FOR USING THE SAME. | |
| ECSP21046332A (en) | MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO THE BETA REGION OF THE HUMAN T-CELL RECEPTOR FAMILY TRBV-9 AND METHODS FOR ITS USE | |
| ECSP21044421A (en) | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF |